Biohaven Pharmaceutical Holding Co Ltd. (28)

Browse by Contract Category

Contracts

Separation and Distribution Agreement, dated as of May 9, 2022, by and between Biohaven Pharmaceutical Holding Company Ltd. and Biohaven Research Ltd (Filed With SEC on May 11, 2022)
Agreement and Plan of Merger, dated as of May 9, 2022, by and among Pfizer Inc., Bulldog (BVI) Ltd. and Biohaven Pharmaceutical Holding Company Ltd (Filed With SEC on May 11, 2022)
Membership Interest Purchase Agreement, dated as of February 24, 2022, by and among Biohaven Therapeutics LTD., Knopp Biosciences LLC, Channel Biosciences, LLC and Biohaven... (Filed With SEC on May 10, 2022)
2022 Deferral Election (Filed With SEC on December 30, 2021)
Collaboration Agreement, dated November 9, 2021, by and among Pfizer Ireland Pharmaceuticals, Biohaven Pharmaceutical Holding Company Ltd., Biohaven Pharmaceutical Ireland DAC and... (Filed With SEC on November 12, 2021)
Amendment No. 4 to Financing Agreement, dated as of December 28, 2021, by and between Biohaven Pharmaceuticals Holding Company Ltd., Biohaven Pharmaceuticals, Inc., the guarantors... (Filed With SEC on February 25, 2022)
Amendment No. 1 to Employment Agreement, dated December 14, 2021, by and between Biohaven Pharmaceuticals, Inc. and James Engelhart (Filed With SEC on February 25, 2022)
Employment Agreement, dated December 8, 2021, between the Company and Matthew Buten (Filed With SEC on December 9, 2021)
Consulting Agreement, dated December 5, 2021, between the Company and Declan Doogan (Filed With SEC on December 9, 2021)
Agreement and Plan of Merger, dated November 9, 2021, by and among Biohaven Pharmaceutical Holding Company Ltd., Biohaven Therapeutics Ltd., Atlas Merger Sub and BioShin Ltd (Filed With SEC on November 12, 2021)
Amendment No. 3 and Limited Consent to Financing Agreement, dated November 9, 2021, by and between Biohaven Pharmaceuticals Holding Company Ltd., Biohaven Pharmaceuticals, Inc.,... (Filed With SEC on November 12, 2021)
Subscription Agreement, dated November 9, 2021, by and between Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd (Filed With SEC on November 12, 2021)
Sublicense Agreement, dated November 9, 2021, by and among Pfizer Ireland Pharmaceuticals, Biohaven Pharmaceutical Holding Company Ltd., Biohaven Pharmaceutical Ireland DAC and... (Filed With SEC on November 12, 2021)
Underwriting Agreement, dated as of March 15, 2021, by and between the Company and Goldman Sachs & Co. LLC (Filed With SEC on March 17, 2021)
Agreement and Plan of Merger, dated as of January 1, 2021, by and between Biohaven Pharmaceutical Holding Company Ltd., Biohaven Therapeutics Ltd., Kleo Acquisition, Inc., Kleo... (Filed With SEC on January 8, 2021)
Equity Distribution Agreement, dated as of December 23, 2020, by and between Biohaven Pharmaceutical Holding Company Ltd. and Goldman Sachs & Co. LLC, Piper Sandler & Co., SVB... (Filed With SEC on December 23, 2020)
Series B Preferred Share Purchase Agreement by and (Filed With SEC on November 9, 2020)
Amendment No. 1 (Filed With SEC on November 9, 2020)
Funding Agreement by and (Filed With SEC on November 9, 2020)
Zydis Commercial Supply Agreement, dated as of June 29, 2018, by and between Biohaven Pharmaceuticals, Inc. and Catalent U.K. Swindon Zydis Limited (Filed With SEC on February 26, 2020)
Offer Letter dated April 5, 2017 by and between Biohaven Pharmaceuticals, Inc. and Elyse Stock (Filed With SEC on February 26, 2020)
Employment Agreement dated February 1, 2014 by and between Biohaven Pharmaceuticals, Inc. and Kimberly A. Gentile (Filed With SEC on February 26, 2020)
Employment Agreement dated March 30, 2019 by and between Biohaven Pharmaceuticals, Inc. and William Jones, Jr (Filed With SEC on February 26, 2020)
Description of Biohaven's Securities Registered under Section 12 of the Exchange Act (Filed With SEC on February 26, 2020)
Underwriting Agreement, dated as of January 28, 2020, by and between the Company and Goldman Sachs & Co. LLC (Filed With SEC on January 30, 2020)
Underwriting Agreement, dated as of June 18, 2019 by and among the Company and Goldman Sachs & Co. LLC and Piper Jaffray & Co., as Representatives of the several Underwriters... (Filed With SEC on June 21, 2019)
Series A Preferred Share Purchase Agreement, dated as of March 18, 2019 (Filed With SEC on May 8, 2019)
PRV Transfer Agreement (Filed With SEC on March 18, 2019)